Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

X

Manasi Vaidya

22 Jul 2021

Comment

LoA Update: Janssen’s Sirturo plans hit a slump with suspension for Phase III trial in mycobacterium avium complex-lung disease

22 Jul 2021

07 Jul 2021

Comment

LoA Update: Galapagos’ potential to move GLPG-3970 into next development phase improves by nine points with Phase II ulcerative colitis trial’s completion

07 Jul 2021

07 Jul 2021

Comment

LoA Update: Ability Pharmaceuticals’ potential to drive Phase I/IIa endometrial cancer drug to next development stage increases to 47%

07 Jul 2021

01 Jul 2021

Comment

Post-ASCO News Alert: Janssen and Daiichi’s targeted strategies can differentiate with finessed biomarkers but may go the all-comer route post-Tagrisso in EGFR-mutated NSCLC

01 Jul 2021

30 Jun 2021

Comment

Post-ASCO News Alert: Janssen’s Rybrevant/lazertinib combination stimulates expert debate on Rybrevant monotherapy potential after Tagrisso in EGFR-mutated NSCLC setting

30 Jun 2021

30 Jun 2021

Comment

LoA Update: Pipeline Therapeutics’ PIPE-505 for hearing loss vaults nine points in chances to advance to next development stage after Phase I/IIa completion

30 Jun 2021

29 Jun 2021

Comment

LoA Update: Sanofi/Regeneron’s approval chances in polymyalgia rheumatica slack after Phase III Kevzara trial termination

29 Jun 2021

24 Jun 2021

Comment

Drug development for long Covid-19 in children warrants unique focus on how mechanisms, prevalence differ from adults

24 Jun 2021

21 Jun 2021

Comment

Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza use in niche HR+ gBRCA-mutant breast cancer subgroup could compete with Verzenio

21 Jun 2021

17 Jun 2021

Comment

Post-ASCO News Alert: Merck’s KEYNOTE-564 data heralds early adjuvant Keytruda use in renal cancer

17 Jun 2021